Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03740165
Title	Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	No
Sponsors	Merck Sharp & Dohme LLC
Indications	peritoneum cancer fallopian tube cancer ovary epithelial cancer
Therapies	Bevacizumab + Carboplatin + Paclitaxel Carboplatin + Paclitaxel Carboplatin + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Carboplatin + Olaparib + Paclitaxel + Pembrolizumab Bevacizumab + Carboplatin + Paclitaxel + Pembrolizumab
Age Groups:	senior \| adult
Covered Countries	USA \| TUR \| POL \| ITA \| ISR \| HUN \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BEL \| AUS